Found: 11
Select item for more details and to access through your institution.
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 3, p. 356, doi. 10.1111/bjh.16088
- By:
- Publication type:
- Article
CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e316, doi. 10.1016/j.clml.2019.09.520
- By:
- Publication type:
- Article
MYD88 and CXCR4 Mutation Rates by Allele-Specific PCR Compared with Diagnostic Next Generation Sequencing Panels in Patients with Waldenstrom's Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e317, doi. 10.1016/j.clml.2019.09.521
- By:
- Publication type:
- Article
The BCR component SYK is activated by mutated MYD88 and the combined inhibition of SYK and BTK produces synthetic lethality in MYD88 driven B-cell lymphomas.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e338, doi. 10.1016/j.clml.2019.09.556
- By:
- Publication type:
- Article
Mutated MYD88 regulates transcription of the pro-survival kinase HCK in MYD88 driven B-cell lymphomas.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e338, doi. 10.1016/j.clml.2019.09.557
- By:
- Publication type:
- Article
Distribution of circulating tumor cells in Waldenström's Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e337, doi. 10.1016/j.clml.2019.09.554
- By:
- Publication type:
- Article
Cell-Free DNA as Alternative to Bone Marrow CD19+ Selection for Diagnostic MYD88 L265P in Waldenstrom's Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e311, doi. 10.1016/j.clml.2019.09.511
- By:
- Publication type:
- Article
Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e39, doi. 10.1016/j.clml.2019.09.060
- By:
- Publication type:
- Article
Impact of Chromosome 6q Deletions in Multiple Myeloma and Waldenström's Macroglobulinemia by Next Generation RNA Sequencing.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e39, doi. 10.1016/j.clml.2019.09.059
- By:
- Publication type:
- Article
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41408-020-0277-6
- By:
- Publication type:
- Article
Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 4, p. 372, doi. 10.1002/ajh.25712
- By:
- Publication type:
- Article